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ABSTRACT
Introduction: End-stage renal disease is
associated with high cardiovascular mortality.
The prognostic importance of milder degrees of
renal impairment in patients who have had an
acute coronary syndrome (ACS) is less well
defined. The purpose of this study was to
evaluate the impact of baseline renal
dysfunction assessed by estimated glomerular
filtration rate (GFR) on mortality in patients
admitted with an ACS.
Methods: We studied all patients with an ACS
consecutively admitted to an Intensive Cardiac
Care Unit over 18 months. The GFR was
estimated by means of the four-component
Modification of Diet in Renal Disease study
equation. Patients were grouped according to
their estimated GFR (less than 45.0; 45.0 to
59.9; 60.0 to 74.9; and at least 75.0
ml/min/1.73 m2). Primary outcome was death
from any cause.
Results: The mean age of the 589 study
patients was 64.1 years, 73.7% were male, and
49.2% had an ACS with ST-segment elevation.
Arterial hypertension, diabetes mellitus, prior
myocardial infarction, and Killip class >I were
incrementally more common across increasing
renal dysfunction strata (p<0.01). The use of
reperfusion therapy, beta-blockers, and
coronary angioplasty was lower in groups with
reduced estimated GFR (p<0.001). Overall six-
month mortality was 13.6%. Using the group
with an estimated GFR of at least 75.0
ml/min/1.73 m2 as the reference group yielded
odds ratios for six-month mortality that
increased with the degree of renal impairment.
After adjusting for baseline characteristics,
impaired renal function remained associated
RESUMO
Impacto prognóstico da disfunção renal
moderada na síndrome coronária aguda
Introdução: A doença renal terminal encontra-
-se associada a elevada mortalidade
cardiovascular. A importância prognóstica de
graus mais ligeiros de disfunção renal em
doentes que tiveram uma síndrome coronária
aguda (SCA) não está definida. O objectivo
deste estudo foi avaliar o impacto da disfunção
renal basal avaliada pela taxa de filtração
glomerular estimada (TFG) na mortalidade em
doentes admitidos com uma SCA.
Métodos: Foram estudados todos os doentes com
uma SCA admitidos de forma consecutiva numa
Unidade de Cuidados Intensivos Cardíacos ao
longo de 18 meses. A TFG foi estimada através
da equação do estudo Modification of Diet in
Renal Disease. Os doentes foram agrupados de
acordo com a TFG estimada (<45,0; 45,0 -
59,9; 60,0 - 74,9; e pelo menos 75,0
ml/min/1,73 m2). Considerou-se como evento
primário a morte por qualquer causa.
Resultados: A idade média dos 589 doentes
incluídos foi 64,1 anos, 73,7% eram homens e
49,2% tiveram uma SCA com supra-
-desnivelamento do segmento ST. Verificou-se
que a prevalência de hipertensão arterial,
diabetes mellitus e enfarte do miocárdio prévio,
e a apresentação em classe de Killip >I
aumentava com o agravamento da disfunção
renal (p <0,01). A utilização de terapêutica de
reperfusão, beta-bloqueadores e angioplastia
coronária percutânea foi inferior nos grupos
uma TFG estimada reduzida (p <0,001). A
mortalidade global aos seis meses foi de
13,6%. Utilizando o grupo com uma TFG
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INTRODUCTION
Chronic kidney disease (CKD) is definedas persistent kidney damage, as reflected
by a glomerular filtration rate (GFR) of less than
60.0 ml per minute per 1.73 m2 of body surface
area for more than three months (1). CKD is
a poorly recognized but important risk factor
for cardiovascular disease (2). Death from
cardiovascular disease is 10 to 30 times higher in
dialysis patients than in the general population (3).
During the past 15 years, the burden of
cardiovascular disease-related morbidity and
mortality in the general population has improved
markedly. However, cardiovascular disease-
related morbidity and mortality in patients with
CKD has remained almost unchanged, perhaps
because of poor recognition of the impact of CKD
on the biology of cardiovascular disease and, to
some extent, the lack of well-designed
prospective studies to define the role of treatment
of targeted risk factors in patients with CKD (2).
Renal dysfunction has proved to be an
important determinant of mortality in the follow-
up of patients who have undergone coronary
artery bypass grafting (4) or a percutaneous
coronary intervention (5), and those who have
suffered an acute myocardial infarction (6-9).
Among patients with end-stage renal disease, the
two-year mortality rate after myocardial infarction
is approximately 50%, twice the mortality rate
after myocardial infarction in the general
population (10). However, limited information exists
on the risks associated with lesser degrees of
renal impairment in patients who have had an
acute coronary syndrome (ACS). Most of the304
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with increased mortality. The multivariable-
adjusted odds ratio for six-month mortality in
patients with mild renal impairment (GFR 60.0
to 74.9 ml/min/1.73 m2) was 2.71 (95%
confidence interval [CI] 1.09 to 6.69),
compared with 7.53 (95% CI, 3.21 to 17.71)
and 8.10 (95% CI, 3.18 to 20.60) in patients
with moderate and more severe renal
dysfunction, respectively.
Conclusions: Baseline renal dysfunction, as
assessed by estimated GFR, is a potent and
easily identifiable determinant of outcome after
an ACS. Even mild levels of renal impairment
are independently associated with increased
mortality after an ACS.
Key words 
Acute coronary syndrome; Myocardial infarction; Renal
function; Renal failure; Chronic kidney disease; Glomerular
filtration rate; Creatinine; Prognosis; Coronary artery disease
estimada de pelo menos 75,0 ml/min/1,73 m2
como o grupo de referência obtiveram-se odds
ratios para a mortalidade aos seis meses que
aumentaram à medida que o grau de
comprometimento renal também aumentava.
Após ajuste para o efeito das características
basais, a disfunção renal permaneceu
associada a aumento da mortalidade. Na
análise multivariável o odds ratio para a
mortalidade aos seis meses nos doentes com
disfunção renal ligeira (TFG estimada entre
60,0 e 74,9 ml/min/1,73m2) foi de 2,71
(intervalos de confiança 95% 1,09 - 6,69), em
comparação com 7,53 (IC 95% 3,21 -17,71) e
8,10 (IC 95% 3,18 a 20,60) em doentes com
disfunção renal moderada e mais severa,
respectivamente.
Conclusões: A disfunção renal basal, avaliada
pela TFG estimada, é um determinante
importante e facilmente identificável de
prognóstico após uma SCA. Mesmo níveis
ligeiros de comprometimento da função renal
estão associados de forma independente a
aumento da mortalidade após uma SCA.
Palavras-Chave
Síndrome coronária aguda; Enfarte do miocárdio; 
Função renal; Insuficiência renal; Doença renal crónica;
Taxa de filtração glomerular; Creatinina; Prognóstico; 
Doença coronária
studies that found renal failure was a prognostic
factor for ischemic heart disease were performed
in selected patients, such as patients from
clinical trials or seriously ill patients (4-6, 9, 11, 12), and
so the findings cannot be readily generalized.
Furthermore, the majority of what is known
relates to serum creatinine level, which is an
insensitive indicator of renal function owing to
nonlinear associations with GFR that vary
according to age, gender, race, and lean body
mass (7, 13). Consequently, the United States
National Kidney Foundation uses GFR rather
than serum creatinine level to define renal
dysfunction (1).
The purpose of this study was to quantify the
impact of baseline renal dysfunction assessed by
estimated glomerular filtration rate (eGFR) on
mortality in unselected patients admitted with an
ACS. 
METHODS
Patients
The study population comprised 589
consecutive patients who were admitted to our
Intensive Cardiac Care Unit (ICCU) with ACS
between July 2003 and December 2004. The
inclusion criteria were a history of chest pain at
rest or other symptoms suggestive of an ACS, with
the most recent episode occurring within 24 h of
admission. This could be associated with either
transient or persistent ST-segment elevation,
ST-segment depression, or T-wave inversion on
the electrocardiogram, or elevated levels
of biomarkers of myocardial damage. The
biomarkers used were cardiac troponin I (cTnI)
and creatine kinase MB mass assay (CK-MB),
with a threshold for positivity of 0.06 and 3.5
ng/ml, respectively. Although this was a
retrospective study, all the clinical and laboratory
data were collected prospectively and recorded
on a computer database of ACS patients admitted
to our institution’s ICCU.
Determination of renal function
Serum creatinine levels were measured during
the first 12 hours. The GFR was estimated using
the four-component Modification of Diet in Renal
Disease (MDRD) equation (6, 14) presented below:
Estimated GFR (ml per minute per 1.73 m2 of
body surface area) = 186 x (serum creatinine
[mg/dl])-1.154 x (age [in years])-0.203
For women, the value was multiplied by
0.742.
Patients were categorized into four groups
based on eGFR in 15 ml increments (less than
45.0, 45.0 to 59.9, 60.0 to 74.9, and at least 75.0
ml/min/1.73 m2), incorporating the guidelines of
the National Kidney Foundation (1), and each
category was analyzed separately. The population
was also divided into 2 subgroups according to
creatinine concentrations at the time of admission
(greater than or less than 1.2 mg/dl for men or 0.9
mg/dl for women, which are the upper limits of
this test in our hospital’s laboratory). 
Outcomes
We defined all-cause mortality as the primary
endpoint in the six-month follow-up.
Follow-up
Patients were monitored for at least six months
or until the primary endpoint was reached.
Follow-up was by telephone, and by review of the
databases and medical records of the hospital.
Follow-up at six months was complete in 565
(96.0%) patients. 
Statistical analysis
Discrete variables were expressed as
percentages and comparisons made with the chi-
square test. Continuous variables were described
as means ± standard deviation and compared
with ANOVA. A test for trend across ordered
groups was performed for the four eGFR groups.
Multivariable logistical regression analysis was
performed to identify independent predictors of
six-month mortality, including variables that
showed potential statistical significance in
univariate analysis (p<0.10). Kaplan-Meier
curves were generated for mortality through six
months of follow-up. The log-rank test was used
to test the equality of the survival function across
groups, and the test for trend of the survival
function was performed across the ordered
groups. All p values were two-sided, and a p
value of less than 0.05 was considered to indicate
statistical significance. Statistical analyses were
performed using SPSS version 13.0 (SPSS Inc.,
Chicago, Illinois, USA).
305
SÉRGIO NABAIS, et al
Rev Port Cardiol 2008; 27: 303-12  
RESULTS
Baseline characteristics
The study included 589 patients who were
admitted consecutively to our ICCU and who met
the inclusion criteria. Of these, 434 (73.7%) were
men, and mean age was 64.1±12.8 years; 18.5%
had suffered a previous infarction, 45.7% had
dyslipidemia, 25.0% were diabetic, 24.4% were
current smokers, and 57.7% had a history of
hypertension. Thirty-one (5.3%) patients had a
final diagnosis of unstable angina, 268 (45.5%)
had non-ST-segment elevation myocardial
infarction, and the remaining 290 (49.2%) had ST-
segment elevation myocardial infarction (STEMI).
The baseline estimated GFR was normally
distributed. Mean (±SD) estimated GFR was
82.8±30.7 ml per minute per 1.73 m2 (range, 11.7
to 191.1). A total of 345 (58.6%) patients had an
estimated GFR of at least 75.0 ml/min/1.73 m2,
183 (17.5%) had an estimated GFR of 60.0 to
74.9 ml/min/1.73m2, 81 (13.8%) had an estimated
GFR of 45.0 to 59.9 ml/min/1.73 m2, and 60
(10.2%) had an estimated GFR of less than 45.0
ml/min/1.73 m2. One hundred forty-one (24.0%)
patients met the estimated GFR criteria for
chronic kidney disease (less than 60.0
ml/min/1.73 m2). There were no patients on
chronic dialysis treatment in the cohort. The
absolute difference in mean serum creatinine
level between groups was 0.1 to 0.8 mg/dl (Fig. 1).
The proportions of patients with coexisting
conditions at baseline increased with decreasing
estimated GFR (Table I). Patients with lower
estimated GFR had higher rates of diabetes,
hypertension, previous myocardial infarction,
and previous stroke. A lower estimated GFR was
also associated with older age and female
gender. However, these variables were used in
the determination of estimated GFR. Cigarette
smoking was less frequent among patients with
renal impairment. Patients with renal dysfunction
presented less often with ST-segment elevation
ACS, had higher heart rates and were more often
in Killip class II to IV on admission. The use
of cardiovascular pharmacotherapies (aspirin,
statins, and angiotensin-converting enzyme
inhibitors) before the admission event was more
frequent in patients with impaired kidney
function (Table I).
Regarding management practices, the use of
reperfusion therapy (almost always with
thrombolytic agents), beta-blockers, coronary
angiography, and percutaneous coronary
revascularization procedures was lower among
patients with impaired renal dysfunction (Table II).
Clinical outcomes
Overall in-hospital mortality was 6.1%; six-
month mortality was 13.6%. Elevated serum
creatinine at presentation was associated with
increased mortality in both men and women (Fig.
2). Table III displays variables associated with
six-month overall mortality on univariate
analysis. Decreasing estimated GFR was
associated with increasing in-hospital and six-
month mortality rates (Table II). Using the group
with an estimated GFR of at least 75.0
ml/min/1.73m2 as the reference group, the
unadjusted odds ratio for six-month mortality for
patients in the lowest GFR category (less than
45.0 ml/min/1.73m2) was 20.00 (95% confidence
interval [CI], 9.15 to 43.74), as compared with
15.78 (95% CI, 7.55 to 32.98) and 3.68 (95% CI,
1.60 to 8.47) for patients with moderate and mild
renal impairment, respectively (Table III).
Kaplan-Meier curves show that mortality
increased early during the follow-up and
continued to separate up to six months of follow-
up in patients with moderate and more severe
renal dysfunction (Fig. 3).
Impaired renal function was associated with
increased six-month mortality rates in both non-306
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Figure 1. Box-and-whisker plot of serum creatinine level (mg/dl)
by estimated glomerular filtration rate (ml/min/1.73 m2) category.
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Figure 2. Kaplan-Meier curves for overall mortality in men and women with acute coronary syndromes stratified according to admission
serum creatinine concentrations.
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ml/min/1.73 m2
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27.2
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23.5
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136.5±28.8
75.2±15.6
81.2±22.1
GFR 60.0-74.9
ml/min/1.73 m2
(n=183)
66.9±12.0
1.1±0.1
68.1±4.1
29.1
46.6
22.3
62.1
56.3
17.5
24.2
21.4
4.9
1.9
4.9
4.9
1.9
27.2
18.4
24.3
25.2
25.2
137.2±26.0
77.1±16.3
78.1±17.6
GFR >75.0
ml/min/1.73 m2
(n=345)
59.3±11.9
0.8±0.1
102.9±21.7
14.5
53.0
18.8
52.2
44.9
32.8
21.1
14.2
3.2
3.2
6.7
4.9
0.9
17.7
14.2
20.0
18.0
12.8
138.4±24.2
78.7±15.5
73.7±17.7
P
<0.001
<0.001
<0.001
<0.001
0.011
<0.001
0.009
0.076
<0.001
0.26
0.005
0.37
0.62
0.83
0.001
0.30
0.02
0.19
0.006
0.02
0.001
0.8
0.08
<0.001
Characteristic
Age (years)
Creatinine (mg/dl)
eGFR (ml/min/1.73 m2)
Female (%)
ST-segment elevation ACS (%)
Diabetes mellitus (%)
Hypertension (%)
Dyslipidemia (%)
Current smoking (%)
BMI >30 (%)
Prior myocardial infarction (%)
Prior PCI (%)
Prior CABG (%)
History of angina (%)
Prior stroke (%)
History of PVD (%)
Baseline medication (%)
Aspirin
Beta-blocker
Statin
ACE inhibitor
Killip class >I on admission (%)
Blood pressure (mmHg)
Systolic
Diastolic
Heart rate (bpm)
Table I
Baseline characteristics of the patients according to estimated GFR
eGFR: estimated glomerular filtration rate; ACS: acute coronary syndrome; BMI: body mass index (weight in kg divided by square of height in meters);
PVD: peripheral vascular disease
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GFR <45.0 
ml/min/1.73 m2
(n=60)
100
61.7
85.0
86.7
7.1
35.6
5.0
6.8
22.7
68.3
95.7
67.4
89.1
93.5
21.7
42.9
GFR 45.0-59.9
ml/min/1.73 m2
(n=81)
98.8
67.9
87.7
84.0
34.2
33.3
4.9
7.4
44.8
61.3
100.0
75.7
88.6
81.4
16.0
37.2
GFR 60.0-74.9
ml/min/1.73 m2
(n=183)
99.0
82.5
91.3
88.3
64.4
59.8
12.6
11.8
34.4
54.4
98.0
88.0
93.0
90.0
2.9
12.1
GFR >75.0
ml/min/1.73 m2
(n=345)
99.7
91.0
91.9
87.0
58.1
69.9
20.6
10.5
22.0
52.9
95.8
86.9
93.2
84.9
2.0
3.6
P
0.52
<0.001
0.57
0.99
<0.001
<0.001
<0.001
0.63
0.022
0.11
0.27
<0.001
0.49
0.17
<0.001
<0.001
Characteristic
In-hospital medication (%)
Aspirin
Beta-blocker
Statin
ACE inhibitor
Reperfusion therapy¶
Procedure (%)
Cardiac catheterization
PCI
CABG
Three vessel / left main CAD (%)
Left ventricular systolic
dysfunction (%)
Discharge medication (%)
Aspirin
Beta-blocker
Statin
ACE inhibitor
In-hospital mortality (%)
Six-month mortality (%)
Table II
Management, angiographic and echocardiographic features, and outcomes of patients according to
estimated glomerular filtration rate
ACE: angiotensin-converting enzyme; ¶ In ST-segment elevation acute coronary syndromes; CAD: Coronary artery disease
OR (95% CI)
1.10 (1.07-1.14)
0.23 (0.09-0.55)
2.83 (1.72-4.66)
0.57 (0.34-0.94)
1.92 (1.16-3.19)
1.03 (1.02-1.04)
3.02 (2.21-4.14)
3.68 (1.60-8.47)
15.78 (7.55-32.98)
20.00 (9.15-43.74)
1.54 (0.97-2.46)
1.56 (0.93-2.59)
P
<0.001
<0.001
<0.001
0.029
0.01
<0.001
<0.001
0.002
<0.001
<0.001
0.068
0.090
Variable
Age (per year)
Current smoking
Diabetes
Dyslipidemia
Female
Heart rate
Killip class
eGFR 60.0-74.9 
ml/min/1.73 m2¶
eGFR 45.0-59.9 
ml/min/1.73 m2¶
eGFR <45.0 
ml/min/1.73 m2¶
LVSD
Hypertension
Table III
Univariate analysis - variables with potential
statistical significance (p<0.10)
eGFR: estimated glomerular filtration rate; LVSD: left ventricular systolic
dysfunction;  ¶The group with an estimated glomerular filtration rate of at
least 75.0 ml/min/1.73 m2 served as the reference group
OR (95% CI)
1.05 (1.01-1.08)
1.50 (1.02-2.21)
2.71 (1.09-6.69)
7.53 (3.21-17.71)
8.10 (3.18-20.60)
P
0.01
0.04
0.032
<0.001
<0.001
Variable
Age (per year)
Killip class
eGFR 60.0-74.9  
ml/min/1.73 m2¶
eGFR 45.0-59.9 
ml/min/1.73 m2¶
eGFR <45.0 
ml/min/1.73 m2
Table IV
Multivariate analysis - independent predictors of
six-month mortality
eGFR: estimated glomerular filtration rate; ¶The group with an estimated
glomerular filtration rate of at least 75.0 ml/min/1.73 m2 served as the
reference group
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ST-segment elevation ACS and STEMI (Fig. 4-A).
In addition, six-month mortality rates increased
with declining estimated GFR when patients
were stratified by the presence or absence of a
history of hypertension or diabetes, which are
known cardiovascular risk factors and
independent predictors of renal disease
development and progression (Figs. 4-B and
4-C). Furthermore, impaired renal function was
associated with increased mortality in the follow-
up of patients with and without signs of heart
failure on admission (Fig. 4-D). 
Mildly to more severely impaired renal
function was associated with increased six-month
mortality in a multivariate model including
variables that showed potential statistical
significance in univariate analysis (p<0.10)
(Table IV). In the group with the lowest estimated
GFR, the adjusted odds ratio for six-month
mortality was 8.10 (95% CI, 3.18 to 20.60),
compared with 7.53 (95% CI, 3.21 to 17.71) in
the group with an estimated GFR of 45.0 to 59.9
ml/min/1.73 m2, and 2.71 (95% CI, 1.09 to 6.69)
in the group with mild renal impairment (GFR
60.0 to 74.9 ml/min/1.73 m2). Considered as a
continuous variable, for baseline estimated
GFR values below 91.0 ml/min/1.73 m2, the
multivariate-adjusted odds ratio for six-month
mortality for each 10-unit reduction in estimated
GFR was 1.29 (95% CI, 1.10 to 1.52).
DISCUSSION
This single-center observational study
extends previous reports regarding the
association of renal dysfunction and increased
mortality among patients who have had an acute
coronary syndrome (6, 7, 15). In the presence of non-
ST-segment elevation and ST-segment elevation
ACS, reduced estimated GFR on presentation
is associated with increased mortality,
independent of other conventional risk factors.
Onset of CKD is associated with an increased
tendency for the development of cardiovascular
disease-related events (16, 17). Persons with CKD are
predisposed to three types of cardiovascular
disease - atherosclerosis, arteriosclerosis, and
cardiomyopathy - compared with age- and
gender-matched persons with normal kidney
function (2).
Glomerular filtration rate is accepted as the
best overall measure of kidney function (18). It is
measured as the urinary or plasma clearance of
an ideal filtration marker such as inulin or
alternative exogenous markers. However, this
method is complex, expensive, and difficult to
perform in routine clinical practice (18). Several
reliable equations incorporating clinical
variables to estimate GFR are available. In this
study, we used GFR estimated with the four-
component MDRD study equation (14), which is
more accurate and provides a better assessment
of renal function in elderly patients and
women (6, 19). This equation does not require the
weight of the subject, an advantage over other
formulae for estimating filtration. Furthermore, a
recent American Heart Association science
advisory recommends that all adult patients with
cardiovascular disease be screened for renal
disease using GFR estimated by the MDRD study
equation and a test for microalbuminuria (20).
The use of estimated GFR revealed wider
differences in renal function than those evident
from serum creatinine levels. Differences in the
levels of serum creatinine between groups
appeared small, whereas the differences in
mortality after an ACS were large (Figs. 1 and 3).
In agreement with recent studies (6, 15),
approximately one-quarter (24%) of the patients
met the estimated GFR criteria for chronic
kidney disease. 
Previous large-scale studies have shown that
reduced renal function was independently 309
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Figure 3. Kaplan-Meier curve for overall mortality in patients
with acute coronary syndromes stratified according to estimated
glomerular filtration rate (ml/min/1.73 m2) on admission.
associated with increased risk of death and
cardiovascular events (6, 9). Our study documents
the association of renal dysfunction with
increased mortality, in a broad population of
consecutive patients with ACS. Below 91
ml/min/1.73m2, each 10-unit decrement in
baseline estimated GFR was associated with a
29% increase in mortality at six-month follow-up.
Assessment of renal function, however, is not
used in the most widely used scores for early risk
stratification on admission of patients with ACS(21,
22). In a recent comparison of the prognostic value
of three ACS risk scores (21-23), the best
performance for one-year prognosis was achieved
by the GRACE score, the only risk score
including renal function determination (by means
of serum creatinine level) in its composition (24). 
The mechanisms by which renal dysfunction
increases cardiovascular risk are poorly
understood. Patients with renal dysfunction are at
high risk partly because of the high prevalence of
multiple risk factors, including older age,
diabetes, hypertension, and previous myocardial
infarction, as shown in Table I. In addition, these
patients present with a less favorable clinical
picture regarding Killip class. Still, in our study,
even a mild reduction in estimated glomerular
filtration rate was independently associated with
increased mortality in multivariate analyses
adjusting for the effect of several potentially
confounding risk factors.
Proposed specific cardiovascular risk factors
contributing to the vasculopathy induced by renal
disease include hyperhomocysteinemia (25),
elevated levels of lipoprotein (a) and oxidized
low-density lipoproteins (LDL), endothelial
dysfunction, diminished vascular nitric oxide
production (26), and elevated uric acid levels (1). It
has also been proposed that reduced secretion of
erythropoietin and insulin-like growth factor may
also specifically contribute to an increased risk of
thrombotic cardiovascular events by inhibiting
vascular repair (27). The chronic anemia and
volume overload associated with severe renal
dysfunction may also contribute to the increased
vascular stiffness observed in these patients,
which may be associated with higher
cardiovascular mortality.310
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Figure 4. Overall six-month mortality rates according to estimated glomerular filtration rate category, stratified by type of acute coronary
syndrome (A), history of diabetes mellitus (B) or hypertension (C), and Killip class on admission (D).
Furthermore, patients with mild to more
severe renal impairment were less likely to
receive guidelines-oriented therapeutic
strategies, namely reperfusion therapy, beta-
blockers, and percutaneous coronary
revascularization procedures (Table II). These
findings are in agreement with previous studies,
which report that patients with chronic kidney
disease receive less effective risk-factor
modification and intervention (so-called
“therapeutic nihilism”) (6, 9, 28-30). Potential reasons
include hemodynamic and cardiovascular
instability, and concern about worsening renal
function and toxic effects of drugs related to
reduced filtration (1, 6, 13, 28, 29). In this study, patients
with renal impairment were as likely as other
patients to receive other risk-modifying
cardiovascular medications, such as aspirin,
angiotensin-converting enzyme (ACE) inhibitors,
and statins. It was reported that patients with
renal impairment have an increased risk of toxic
effects of some of the therapeutic agents used
in ACS (contrast agents, ACE inhibitors,
glycoprotein IIb/IIIa inhibitors), and an increased
risk of bleeding complications (8, 9). Many
cardiovascular trials have excluded patients
with renal disease, limiting our knowledge of
the efficacy and safety of cardiovascular
medications and interventional strategies in these
patients. However, it has been demonstrated that
cardiovascular drugs and coronary interventional
strategies can safely be administered to patients
with renal insufficiency, when appropriately
monitored, and yield similar benefits to those
observed in the general population (6). 
LIMITATIONS
This was an observational and non-
randomized study, and as such, both identified
and unidentified confounders may have
influenced the outcomes. Another potential
limitation of our study is that the measurement of
creatinine, although performed at presentation,
may have been influenced by the hemodynamic
state of the patient and might not accurately
reflect baseline renal function.
CONCLUSIONS
Baseline renal dysfunction, as assessed by
estimated GFR, is a potent and easily identifiable
determinant of outcome in patients with ACS.
Mild to more severe renal impairment is
independently associated with increased
mortality after an ACS at six-month follow-up.
This marker is readily obtained, is available to
all hospitals, provides valuable prognostic
information for immediate stratification, and
should be determined in all patients with ACS. In
agreement with previous studies, our data support
the development and application of more
aggressive strategies for preventing and treating
ACS in patients with renal insufficiency, in
order to optimize outcomes in this high-risk
population.
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